Publication in Nature Communications Highlights the Preclinical Development of SYNB1891 and its Potential as a Dual Innate Immune Activator to Stimulate an Immune Response in Difficult to Treat Tumors
About Innate Pharma S.A.
- NASDAQ: $IPHA
- Notified: $6.54
- 05:47 EDT
